WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317137
CAS#: 210421-74-2 (sodium salt)
Description: Sitaxentan, also known as TBC-11251 and IPI 1040, is a medication for the treatment of pulmonary arterial hypertension (PAH). It was marketed as Thelin. In 2010, Pfizer voluntarily removed sitaxentan from the market due to concerns about liver toxicity. Sitaxentan is a small molecule that blocks the action of endothelin (ET) on the endothelin-A (ETA) receptor selectively (by a factor of 6000 compared with the ETB).
MedKoo Cat#: 317137
Name: Sitaxentan sodium
CAS#: 210421-74-2 (sodium salt)
Chemical Formula: C18H14ClN2NaO6S2
Exact Mass:
Molecular Weight: 476.88
Elemental Analysis: C, 45.34; H, 2.96; Cl, 7.43; N, 5.87; Na, 4.82; O, 20.13; S, 13.45
Sitaxentan sodium, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).
Synonym: TBC-11251; TBC11251; TBC 11251; TBC-11251 sodium salt, Thelin; Sitaxentan sodium
IUPAC/Chemical Name: sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide
InChi Key: MDTNUYUCUYPIHE-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H14ClN2O6S2.Na/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18;/h3-5,7H,6,8H2,1-2H3;/q-1;+1
SMILES Code: O=C(C(SC=C1)=C1S(N([Na])C2=C(C(C)=NO2)Cl)(=O)=O)CC3=C(C)C=C(OCO4)C4=C3
The following data is based on the product molecular weight 476.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Dhaun N, Yuzugulen J, Kimmitt RA, Wood EG, Chariyavilaskul P, MacIntyre IM, Goddard J, Webb DJ, Corder R. Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin A receptor antagonism. J Am Heart Assoc. 2015 Mar 23;4(3):e001624. doi: 10.1161/JAHA.114.001624. PubMed PMID: 25801761; PubMed Central PMCID: PMC4392442.
2: Cross DM, Horsley E, Derzi M, Owen K, Stavros FL. An evaluation of reproductive and developmental toxicity of sitaxentan (thelin) in rats. Birth Defects Res B Dev Reprod Toxicol. 2012 Oct;95(5):327-36. doi: 10.1002/bdrb.21021. Epub 2012 Aug 13. PubMed PMID: 22890981.
3: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 May;32(4):247-88. doi: 10.1358/mf.2010.32.4.1507200. PubMed PMID: 20508873.
4: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jan-Feb;32(1):47-86. PubMed PMID: 20383346.
5: Stavros F, Kramer WG, Wilkins MR. The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol. 2010 Jan;69(1):23-6. doi: 10.1111/j.1365-2125.2009.03541.x. PubMed PMID: 20078609; PubMed Central PMCID: PMC2805874.
6: Agard C, Haloun A, Hamidou MA. [Pulmonary arterial hypertension related to systemic sclerosis in 2008]. J Mal Vasc. 2009 Feb;34(1):7-15. doi: 10.1016/j.jmv.2008.10.008. Epub 2008 Dec 9. Review. French. PubMed PMID: 19081217.
7: Moral MA, Tomillero A. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):149-71. PubMed PMID: 18560631.
Related CAS#
CAS#210421-74-2 (Sitaxentan sodium salt)
CAS#184036-34-8 (Sitaxentan free)
